SEC Form 4 · accession 0001209191-18-002809
IMMUNE DESIGN CORP. · IMDZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jan Henrik ter Meulen
Officer — Chief Scientific Officer
Period of report
Jan 4, 2018
Accepted (ET)
Jan 8, 2018 · 8:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001437786
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 4, 2018 | A | 18,000 | $0.00 | A | 41,020 | D | |
| Common StockF3 | Jan 5, 2018 | S | 1,986 | $4.17 | D | 39,034 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $4.05 | Jan 4, 2018 | A | 90,000 | A | — | Jan 4, 2028 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Immune Design Corp. common stock.
- F2Restricted stock units shall vest in a series of three equal consecutive annual installments beginning on January 4, 2019, subject to the Reporting Person's continuous service through each such date.
- F3The shares were sold pursuant to a Rule 10b5-1 trading plan that was included in the Reporting Person's restricted stock unit agreements, dated January 4, 2016 and January 4, 2017, in order to satisfy a tax liability incurred upon the vesting of restricted stock units on January 4, 2018.
- F4One quarter of the shares underlying the option will vest on January 4, 2019, and the remainder of the shares underlying the option will vest at a rate of 1/24th per month thereafter, subject to the Reporting Person's continuous service through each such date.